Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

116.86 +3.05 (+2.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,621,490
Open 114.18
Bid (Size) 115.00 (100)
Ask (Size) 120.00 (100)
Prev. Close 113.81
Today's Range 113.50 - 118.69
52wk Range 66.83 - 116.00
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
Via Chartmill
News headline image
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc... 
Via StockStory
Topics Retirement

Performance

YTD
+15.2%
+15.2%
1 Month
+22.3%
+22.3%
3 Month
+23.9%
+23.9%
6 Month
+18.3%
+18.3%
1 Year
+70.0%
+70.0%

More News

Read More
News headline image
2 Growth Stocks to Add to Your Roster and 1 We Avoid
Via StockStory
Topics Electric Vehicles
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
From Incyte Biosciences Japan G.K.
Via Business Wire
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability ↗
Via Chartmill
INCYTE CORP (NASDAQ:INCY) Shows Rare Alignment of High Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
Top S&P500 movers in Monday's session ↗
Via Chartmill
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Which S&P500 stocks are gapping on Monday? ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
News headline image
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
From Incyte
Via Business Wire
News headline image
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
From Incyte
Via Business Wire
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
News headline image
Why Incyte (INCY) Stock Is Up Today
Via StockStory
Topics Artificial Intelligence
News headline image
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
Via StockStory
Topics Credit Cards Stocks
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
From Incyte
Via Business Wire
News headline image
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
From Incyte
Via Business Wire
News headline image
3 Profitable Stocks for Long-Term Investors
Via StockStory
News headline image
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Incyte
Via Business Wire
News headline image
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out ↗
Via MarketBeat
News headline image
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
From Genesis Molecular AI and Incyte
Via Business Wire

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 116.86
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 07/02/26 04:00 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 25.99B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 26B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.